If you had chemotherapy with Taxotere and were later left with constantly watering eyes, you are not imagining a connection — a group of lawsuits alleges the drug can scar the tear ducts. Here is what the eye-injury MDL claims and where it stands, including the honest fact that there is no settlement to claim.
Allegations Only · No Settlement Yet
This page describes active litigation. The statements below are unproven allegations. Sanofi has not been found liable, no court has ruled that Taxotere causes eye injuries, no class has been certified, and there is no settlement or claim form at this time. This page is informational and is not legal or medical advice. Do not stop or change any prescribed cancer treatment without consulting your oncologist.
What Is This About?
Taxotere (docetaxel) is a taxane chemotherapy drug marketed by Sanofi and widely used to treat breast and other cancers; generic docetaxel is also sold by other manufacturers. A group of former chemotherapy patients has sued, alleging that the drug caused a specific, lasting eye injury.The claim centers on canalicular stenosis — scarring and narrowing of the small canals that drain tears from the eye into the nose. When those ducts are blocked, tears have nowhere to go, producing chronic excessive tearing known as epiphora, along with related eye problems that in some cases require corrective surgery. Plaintiffs allege Sanofi knew or should have known of this risk and failed to warn patients and their doctors.
The federal cases are consolidated in multidistrict litigation known as MDL 3023, In re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation, before Judge Jane Triche Milazzo in the U.S. District Court for the Eastern District of Louisiana. It was centralized there in 2022. These are individual injury cases coordinated for pretrial handling — not a class action — and the allegations have not been proven.
What Do the Lawsuits Allege?
Plaintiffs allege that docetaxel can be secreted in tears and, over the course of treatment, damage the delicate tear-drainage system — scarring the canaliculi and puncta (the tiny drainage openings) and blocking the nasolacrimal duct. The alleged result is:• Chronic, excessive watering of the eyes (epiphora)
• Blurred vision and irritation from constant tearing
• Blocked or scarred tear-drainage ducts (canalicular / punctal stenosis)
• In some cases, the need for probing, stent placement, or corrective surgery such as a DCR (dacryocystorhinostomy)
The central legal theory is failure to warn — that Sanofi did not adequately alert patients and physicians to the eye-injury risk. Sanofi disputes the allegations, and no court has found that Taxotere causes these injuries. Every causal statement here reflects what plaintiffs allege, not an adjudicated fact.
How This Differs From the Taxotere Hair-Loss Lawsuit
Taxotere has been the subject of two separate litigations, and it is easy to confuse them. The older and larger one, MDL 2740, involves claims of permanent hair loss (alopecia) after Taxotere chemotherapy; it is also in the Eastern District of Louisiana before Judge Milazzo and was created in 2016. The eye-injury cases were organized later into their own MDL, MDL 3023, before the same judge — which is why the two dockets are often mentioned together.The hair-loss litigation has been winding down: it peaked at more than 10,000 cases, Sanofi won both of the bellwether trials that were held (in 2019 and 2021), and thousands of cases were dismissed, leaving a much smaller number of active claims. In 2026 the hair-loss court has been focused on enforcing prior individual settlements rather than trying new cases, and there has been no across-the-board global settlement. The eye-injury MDL is a distinct, younger case with a different alleged injury.
Where the Eye-Injury MDL Stands
As of mid-2026, MDL 3023 remained active, with roughly 140 to 150 actions pending and a docket that has been shrinking month over month. Two developments help frame where it is headed:• In April 2026, the court granted summary judgment to several generic docetaxel manufacturers, dismissing the claims against those generic makers — a result consistent with the federal-preemption law that generally shields generic-drug manufacturers from state-law failure-to-warn claims. Claims against Sanofi, the brand manufacturer, continued.
• No eye-injury bellwether trial had yet been held, and there was no settlement or settlement fund.
Because the eye-injury cases are individually litigated and there is no class settlement, there is no claim form to file and nothing to "claim" on this page. Anyone who believes they developed a lasting tear-duct injury after Taxotere chemotherapy should speak with their physician and, if they wish, a qualified attorney, keeping in mind that statutes of limitations vary by state.
Frequently Asked Questions
What is the Taxotere eye injury lawsuit about?
Plaintiffs allege that Taxotere (docetaxel), a chemotherapy drug marketed by Sanofi, causes canalicular stenosis — scarring and blockage of the tear-drainage ducts — leading to chronic excessive tearing (epiphora) and related eye injuries, some requiring corrective surgery. They allege Sanofi failed to adequately warn patients and physicians of the risk. The federal cases are consolidated in MDL 3023 in the Eastern District of Louisiana. These are unproven allegations.
Is this the same as the Taxotere hair loss lawsuit?
No — they are separate but related. The older Taxotere litigation, MDL 2740, involves claims of permanent hair loss (alopecia) and is also in the Eastern District of Louisiana before Judge Jane Triche Milazzo. The eye-injury cases were later organized into their own MDL, MDL 3023, before the same judge. Both concern the same drug and manufacturer but allege different injuries.
Is there a Taxotere eye injury settlement or claim form?
No. As of mid-2026 there is no settlement, no settlement fund, and no claim form in the Taxotere eye-injury MDL. These are individual product-liability lawsuits handled through each plaintiff's own attorney, not a class action with an online claim portal. There is nothing to claim on this page.
Where does the Taxotere eye injury MDL stand now?
The MDL remained active in mid-2026, with roughly 140 to 150 actions pending and declining month over month. In April 2026 the court granted summary judgment to several generic docetaxel manufacturers, dismissing the claims against those generics on federal-preemption grounds, while claims against Sanofi continued. No eye-injury bellwether trial had yet been held, and no settlement had been reached.
Related Mass Torts & Sources
• Dupixent lymphoma lawsuit (MDL 3180) — another failure-to-warn drug MDL where causation is unproven.• PPI kidney injury lawsuit (MDL 2789) — a drug MDL that resolved through settlements.
• Zostavax shingles vaccine lawsuit (MDL 2848) — a drug MDL that ran into causation-proof problems.
Primary sources: the U.S. Judicial Panel on Multidistrict Litigation (JPML) pending-MDL statistics and its 2022 transfer order creating MDL 3023; the U.S. District Court for the Eastern District of Louisiana MDL 3023 (eye injury) and MDL 2740 (hair loss) case pages; and court orders in the eye-injury litigation.
Important Disclosures
This page is for general informational purposes and does not constitute medical or legal advice. You should consult a qualified attorney about your individual situation and your oncologist about your treatment. OpenClassActions.com is not a law firm and is not a claims administrator, and this page does not create an attorney-client relationship.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
